NEWS

Celcuity's Gedatolisib Falls Short of Primary Endpoint in Breast Cancer Trial

Celcuity (CELC) reported that gedatolisib, a PI3K inhibitor paired with endocrine therapy, did not meet its primary efficacy endpoint in the Phase III Viktoria trial for PIK3CA-mutant hormone receptor-positive breast cancer. BioPharma Dive reported the results were presented at ASCO 2026 on June 2.

The miss represents a setback for a crowded PIK3CA-inhibitor class where competitors including Pfizer (PFE) and Eli Lilly (LLY) have already secured approvals. Gedatolisib's failure to demonstrate superior progression-free survival leaves Celcuity with limited near-term optionality and raises questions about the drug's clinical and commercial viability in a increasingly saturated segment.

BioPharma Dive noted analyst commentary flagged the trial had carried "lofty expectations" ahead of disclosure.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

NEWS

Abivax ulcerative colitis drug shows efficacy but safety signals weigh on shares

Abivax reported that its investigational treatment obefazimod met efficacy endpoints in a Phase 3 trial for ulcerative colitis, yet the stock declined sharply following the announcement as safety concerns overshadowed the clinical win. The company disclosed cases of cancer among trial participants, prompting immediate investor reassessment of the risk-benefit profile.

The disconnect between efficacy and market reaction underscores how biotech investors now weigh safety signals alongside therapeutic promise. For a chronic inflammatory disease with established treatment options, safety data carries disproportionate weight in clinical decision-making—both regulatory and commercial. STAT News reported on the trial results and subsequent share movement on June 1.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.